Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzymeCD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction ofapoptosiswithout crosslinking. Isatuximab also directly inhibitsCD38ectoenzyme activity, which is implicated in many cellular functions^[1][2].

An in-vitro study shows that the combination of Isatuximab with Pomalidomide (an immunomodulatory drug) results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone^[2].

Liquid

1461640-62-9

Please store the product under the recommended conditions in the Certificate of Analysis.